Management der frühen rheumatoiden Arthritis

1.

Zink A, Albrecht K (2016) Wie häufig sind muskuloskeletale Erkrankungen in Deutschland? Z Rheumatol 75:346–353PubMedCrossRef

2.

Hense S, Luque Ramos A, Callhoff J, Albrecht K, Zink A, Hoffmann F (2016) Prävalenz der rheumatoiden arthritis in deutschland auf basis von Kassendaten. Z Rheumatol 75:819–827PubMedCrossRef

3.

Carmona L, Cross M, Williams B, Lassere M, March L (2010) Rheumatoid arthritis. Baillieres Best Pract Res Clin Rheumatol 24:733–745CrossRef

4.

Chang K, Yang SM, Kim SH, Han KH, Park SJ, Shin JI (2014) Smoking and rheumatoid arthritis. IJMS 15:22279–22295PubMedCrossRefPubMedCentral

5.

Crowson CS, Matteson EL, Davis JM, Gabriel SE (2013) Contribution of obesity to the rise in incidence of rheumatoid arthritis. Arthritis Care Res 65:71–77CrossRef

6.

Hedström AK, Stawiarz L, Klareskog L, Alfredsson L (2018) Smoking and susceptibility to rheumatoid arthritis in a swedish population-based case–control study. Eur J Epidemiol 33:415–423PubMedPubMedCentralCrossRef

7.

Myasoedova E, Crowson CS, Kremers HM, Therneau TM, Gabriel SE (2010) Is the incidence of rheumatoid arthritis rising?: Results from olmsted county, minnesota, 1955–2007. Arthritis Rheum 62:1576–1582PubMedPubMedCentralCrossRef

8.

Pedersen JK, Svendsen AJ, Hørslev-Petersen K (2007) Incidence of rheumatoid arthritis in the southern part of denmark from 1995 to 2001. TORJ 1:18–23PubMedCrossRefPubMedCentral

9.

Combe B, Landewe R, Daien CI, Hua C, Aletaha D, Álvaro-Gracia JM et al (2017) 2016 update of the eular recommendations for the management of early arthritis. Ann Rheum Dis 76:948–959PubMedCrossRef

10.

Young A, Dixey J, Cox N, Davies P, Devlin J, Emery P et al (2000) How does functional disability in early rheumatoid arthritis (ra) affect patients and their lives? Results of 5 years of follow-up in 732 patients from the early ra study (eras). Rheumatology 39:603–611PubMedCrossRef

11.

Verstappen SM (2013) Outcomes of early rheumatoid arthritis—the who icf framework. Baillieres Best Pract Res Clin Rheumatol 27:555–570CrossRef

12.

Nikiphorou E, Norton S, Carpenter L, Dixey J, Walsh AD, Kiely P et al (2017) Secular changes in clinical features at presentation of rheumatoid arthritis: Increase in comorbidity but improved inflammatory states. Arthritis Care Res 69:21–27CrossRef

13.

Listing J, Kekow J, Manger B, Burmester G‑R, Pattloch D, Zink A et al (2015) Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, tnfα inhibitors and rituximab. Ann Rheum Dis 74:415–421PubMedCrossRef

14.

Meune C, Touzé E, Trinquart L, Allanore Y (2009) Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. Rheumatology 48:1309–1313PubMedCrossRef

15.

Radovits BJ, Fransen J, Al Shamma S, Eijsbouts AM, van Riel PL, Laan RF (2010) Excess mortality emerges after 10 years in an inception cohort of early rheumatoid arthritis. Arthritis Care Res 62:362–370CrossRef

16.

Lindqvist E, Saxne T, Geborek P, Eberhardt K (2002) Ten year outcome in a cohort of patients with early rheumatoid arthritis: health status, disease process, and damage. Ann Rheum Dis 61:1055–1059PubMedPubMedCentralCrossRef

17.

van Zeben D, Hazes JM, Zwinderman AH, Vandenbroucke JP, Breedveld FC (1994) The severity of rheumatoid arthritis: a 6‑year followup study of younger women with symptoms of recent onset. J Rheumatol 21:1620–1625PubMed

18.

Wiles NJ, Lunt M, Barrett EM, Bukhari M, Silman AJ, Symmons DP et al (2001) Reduced disability at five years with early treatment of inflammatory polyarthritis: Results from a large observational cohort, using propensity models to adjust for disease severity. Arthritis Rheum 44:1033–1042PubMedCrossRef

19.

Bukhari Ma S, Wiles NJ, Lunt M, Harrison BJ, Scott DGI, Symmons DPM et al (2003) Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: results from a large observational inception study. Arthritis Rheum 48:46–53PubMedCrossRef

20.

Boire G, Cossette P, de Brum-Fernandes AJ, Liang P, Niyonsenga T, Zhou ZJ et al (2005) Anti-sa antibodies and antibodies against cyclic citrullinated peptide are not equivalent as predictors of severe outcomes in patients with recent-onset polyarthritis. Arthritis Res Ther 7:R592–R603PubMedPubMedCentralCrossRef

21.

Gorman JD (2006) Smoking and rheumatoid arthritis: another reason to just say no. Arthritis Rheum 54:10–13PubMedCrossRef

22.

Nielen MMJ, van der Horst AR, van Schaardenburg D, van der Horst-Bruinsma IE, van de Stadt RJ, Aarden L et al (2005) Antibodies to citrullinated human fibrinogen (acf) have diagnostic and prognostic value in early arthritis. Ann Rheum Dis 64:1199–1204PubMedPubMedCentralCrossRef

23.

Nyhäll-Wåhlin BM, Jacobsson LTH, Petersson IF, Turesson C, group Bs (2006) Smoking is a strong risk factor for rheumatoid nodules in early rheumatoid arthritis. Ann Rheum Dis 65:601–606PubMedCrossRef

24.

Nell VPK, Machold KP, Stamm TA, Eberl G, Heinzl H, Uffmann M et al (2005) Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann Rheum Dis 64:1731–1736PubMedPubMedCentralCrossRef

25.

Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC et al (2000) The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 43:155–163PubMedCrossRef

26.

Scott IC, Tan R, Stahl D, Steer S, Lewis CM, Cope AP (2013) The protective effect of alcohol on developing rheumatoid arthritis: A systematic review and meta-analysis. Rheumatology 52:856–867PubMedCrossRef

27.

Symmons DPM (2002) Epidemiology of rheumatoid arthritis: determinants of onset, persistence and outcome. Best Pract Res Clin Rheumatol 16:707–722CrossRef

28.

van der Helm-van Mil AHM, le Cessie S, van Dongen H, Breedveld FC, Toes REM, Huizinga TWJ (2007) A prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: how to guide individual treatment decisions. Arthritis Rheum 56:433–440PubMedCrossRef

29.

van der Helm-van Mil AHM, Detert J, le Cessie S, Filer A, Bastian H, Burmester GR et al (2008) Validation of a prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: moving toward individualized treatment decision-making. Arthritis Rheum 58:2241–2247PubMedCrossRef

30.

Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JMW (2002) How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum 46:357–365PubMedCrossRef

31.

Vittecoq O, Incaurgarat B, Jouen-Beades F, Legoedec J, Letourneur O, Rolland D et al (2004) Autoantibodies recognizing citrullinated rat filaggrin in an elisa using citrullinated and non-citrullinated recombinant proteins as antigens are highly diagnostic for rheumatoid arthritis. Clin Exp Immunol 135:173–180PubMedPubMedCentralCrossRef

32.

Wolfe F, Zwillich SH (1998) The long-term outcomes of rheumatoid arthritis: a 23-year prospective, longitudinal study of total joint replacement and its predictors in 1,600 patients with rheumatoid arthritis. Arthritis Rheum 41:1072–1082PubMedCrossRef

33.

van Nies JA, Tsonaka R, Gaujoux-Viala C, Fautrel B, van der Helm-van Mil AH (2015) Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: Does a window of opportunity exist? Results on the leiden early arthritis clinic and espoir cohorts. Ann Rheum Dis 74:806–812PubMedCrossRef

34.

Emery P (1995) Therapeutic approaches for early rheumatoid arthritis. How early? How aggressive? Br J Rheumatol 34(Suppl 2):87–90PubMedCrossRef

35.

Machold KP, Eberl G, Leeb BF, Nell V, Windisch B, Smolen JS (1998) Early arthritis therapy: rationale and current approach. J Rheumatol Suppl 53:13–19PubMed

36.

Boers M (2003) Understanding the window of opportunity concept in early rheumatoid arthritis. Arthritis Rheum 48:1771–1774PubMedCrossRef

37.

O’Dell JR (2002) Treating rheumatoid arthritis early: a window of opportunity? Arthritis Rheum 46:283–285PubMedCrossRef

38.

Emery P, Breedveld FC, Dougados M, Kalden JR, Schiff MH, Smolen JS (2002) Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis 61:290–297PubMedPubMedCentralCrossRef

39.

Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd et al (2010) 2010 rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69:1580–1588PubMedCrossRef

40.

Radner H, Neogi T, Smolen JS, Aletaha D (2014) Performance of the 2010 acr/eular classification criteria for rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 73:114–123PubMedCrossRef

41.

Bukhari M, Lunt M, Harrison BJ, Scott DGI, Symmons DPM, Silman AJ (2002) Erosions in inflammatory polyarthritis are symmetrical regardless of rheumatoid factor status: Results from a primary care-based inception cohort of patients. Rheumatology 41:246–252PubMedCrossRef

42.

Knevel R, Lukas C, van der Heijde D, Rincheval N, Combe B, van der Helm-van Mil AH (2013) Defining erosive disease typical of ra in the light of the acr/eular 2010 criteria for rheumatoid arthritis; results of the data driven phase. Ann Rheum Dis 72:590–595PubMedCrossRef

43.

Sokka T, Pincus T (2009) Erythrocyte sedimentation rate, c‑reactive protein, or rheumatoid factor are normal at presentation in 35 %–45 % of patients with rheumatoid arthritis seen between 1980 and 2004: Analyses from finland and the united states. J Rheumatol 36:1387–1390PubMedCrossRef

44.

Saraux A, Berthelot JM, Chalès G, Le Henaff C, Mary JY, Thorel JB et al (2002) Value of laboratory tests in early prediction of rheumatoid arthritis. Arthritis Rheum 47:155–165PubMedCrossRef

45.

Ioan-Facsinay A, el-Bannoudi H, Scherer HU, van der Woude D, Ménard HA, Lora M et al (2011) Anti-cyclic citrullinated peptide antibodies are a collection of anti-citrullinated protein antibodies and contain overlapping and non-overlapping reactivities. Ann Rheum Dis 70:188–193PubMedCrossRef

46.

Bang H, Egerer K, Gauliard A, Lüthke K, Rudolph PE, Fredenhagen G et al (2007) Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum 56:2503–2511PubMedCrossRef

47.

Damjanovska L, Thabet MM, Levarth EW, Stoeken-Rijsbergen G, van der Voort EI, Toes RE et al (2010) Diagnostic value of anti-mcv antibodies in differentiating early inflammatory arthritis. Ann Rheum Dis 69:730–732PubMedCrossRef

48.

Innala L, Kokkonen H, Eriksson C, Jidell E, Berglin E, Dahlqvst SR (2008) Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides. J Rheumatol 35:1002–1008PubMed

49.

Lee YH, Bae SC, Song GG (2015) Diagnostic accuracy of anti-mcv and anti-ccp antibodies in rheumatoid arthritis: a meta-analysis. Z Rheumatol 74:911–918PubMedCrossRef

50.

Luime JJ, Colin EM, Hazes JMW, Lubberts E (2010) Does anti-mutated citrullinated vimentin have additional value as a serological marker in the diagnostic and prognostic investigation of patients with rheumatoid arthritis? A systematic review. Ann Rheum Dis 69:337–344PubMedCrossRef

51.

Mathsson L, Mullazehi M, Wick MC, Sjöberg O, van Vollenhoven R, Klareskog L et al (2008) Antibodies against citrullinated vimentin in rheumatoid arthritis: Higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides. Arthritis Rheum 58:36–45PubMedCrossRef

52.

Syversen SW, Goll GL, van der Heijde D, Landewé R, Lie BA, Odegård S et al (2010) Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: Results from a 10-year prospective study. Ann Rheum Dis 69:345–351PubMedCrossRef

53.

van der Linden MPM, van der Woude D, Ioan-Facsinay A, Levarht EWN, Stoeken-Rijsbergen G, Huizinga TWJ et al (2009) Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis. Arthritis Rheum 60:2232–2241PubMedCrossRef

54.

Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S et al (2007) Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 146:797–808PubMedCrossRef

55.

Whiting PF, Smidt N, Sterne JAC, Harbord R, Burton A, Burke M et al (2010) Systematic review: accuracy of anti-citrullinated peptide antibodies for diagnosing rheumatoid arthritis. Ann Intern Med 152:456–464; W155–66PubMedCrossRef

56.

Bas S, Perneger TV, Seitz M, Tiercy JM, Roux-Lombard P, Guerne PA (2002) Diagnostic tests for rheumatoid arthritis: comparison of anti-cyclic citrullinated peptide antibodies, anti-keratin antibodies and igm rheumatoid factors. Rheumatology 41:809–814PubMedCrossRef

57.

Berglin E, Johansson T, Sundin U, Jidell E, Wadell G, Hallmans G et al (2006) Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by iga-rf at disease onset. Ann Rheum Dis 65:453–458PubMedCrossRef

58.

Hensvold AH, Frisell T, Magnusson PKE, Holmdahl R, Askling J, Catrina AI (2017) How well do acpa discriminate and predict ra in the general population: a study based on 12 590 population-representative swedish twins. Ann Rheum Dis 76:119–125PubMedCrossRef

59.

Kastbom A, Forslind K, Ernestam S, Geborek P, Karlsson JA, Petersson IF et al (2016) Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the swefot trial. Ann Rheum Dis 75(2):356 (http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/369/CN-01164369/frame.html)PubMedCrossRef

60.

Lindqvist E, Eberhardt K, Bendtzen K, Heinegård D, Saxne T (2005) Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis 64:196–201PubMedCrossRef

61.

Rönnelid J, Wick MC, Lampa J, Lindblad S, Nordmark B, Klareskog L et al (2005) Longitudinal analysis of citrullinated protein/peptide antibodies (anti-cp) during 5 year follow up in early rheumatoid arthritis: Anti-cp status predicts worse disease activity and greater radiological progression. Ann Rheum Dis 64:1744–1749PubMedPubMedCentralCrossRef

62.

van Boekel MAM, Vossenaar ER, van den Hoogen FHJ, van Venrooij WJ (2002) Autoantibody systems in rheumatoid arthritis: Specificity, sensitivity and diagnostic value. Arthritis Res 4:87–93PubMedCrossRef

63.

van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, de Jong BA, Breedveld FC, Verweij CL et al (2004) Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: A prospective cohort study. Arthritis Rheum 50:709–715PubMedCrossRef

64.

Nielen MMJ, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MHMT et al (2004) Specific autoantibodies precede the symptoms of rheumatoid arthritis: A study of serial measurements in blood donors. Arthritis Rheum 50:380–386PubMedCrossRef

65.

Rantapää-Dahlqvist S, de Jong BAW, Berglin E, Hallmans G, Wadell G, Stenlund H et al (2003) Antibodies against cyclic citrullinated peptide and iga rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 48:2741–2749PubMedCrossRef

66.

Mjaavatten MD, Uhlig T, Haugen AJ, Nygaard H, Sidenvall G, Helgetveit K et al (2009) Positive anti-citrullinated protein antibody status and small joint arthritis are consistent predictors of chronic disease in patients with very early arthritis: Results from the nor-veac cohort. Arthritis Res Ther 11:R146PubMedPubMedCentralCrossRef

67.

Syversen SW, Gaarder PI, Goll GL, Ødegård S, Haavardsholm EA, Mowinckel P et al (2008) High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: Results from a 10-year longitudinal study. Ann Rheum Dis 67:212–217PubMedCrossRef

68.

Kastbom A, Strandberg G, Lindroos A, Skogh T (2004) Anti-ccp antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the swedish tira project). Ann Rheum Dis 63:1085–1089PubMedPubMedCentralCrossRef

69.

Sanmartí R, Gómez-Centeno A, Ercilla G, Larrosa M, Viñas O, Vazquez I et al (2007) Prognostic factors of radiographic progression in early rheumatoid arthritis: A two year prospective study after a structured therapeutic strategy using dmards and very low doses of glucocorticoids. Clin Rheumatol 26:1111–1118PubMedCrossRef

70.

Machold KP, Stamm TA, Eberl GJM, Nell VKP, Dunky A, Uffmann M et al (2002) Very recent onset arthritis—clinical, laboratory, and radiological findings during the first year of disease. J Rheumatol 29:2278–2287PubMed

71.

Hetland ML, Ejbjerg B, Horslev-Petersen K, Jacobsen S, Vestergaard A, Jurik AG et al (2009) Mri bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (cimestra). Ann Rheum Dis 68:384–390PubMedCrossRef

72.

Joshua F, Lassere M, Bruyn GA, Szkudlarek M, Naredo E, Schmidt WA et al (2007) Summary findings of a systematic review of the ultrasound assessment of synovitis. J Rheumatol 34:839–847PubMed

73.

Østergaard M, Pedersen SJ, Døhn UM (2008) Imaging in rheumatoid arthritis—status and recent advances for magnetic resonance imaging, ultrasonography, computed tomography and conventional radiography. Best Pract Res Clin Rheumatol 22:1019–1044PubMedCrossRef

74.

Joshua F, Edmonds J, Lassere M (2006) Power doppler ultrasound in musculoskeletal disease: a systematic review. Semin Arthritis Rheum 36:99–108PubMedCrossRef

75.

Strunk J, Backhaus M, Schmidt W, Kellner H (2010) Color doppler sonography for investigation of peripheral joints and ligaments. Z Rheumatol 69:164–170PubMedCrossRef

76.

Dougados M, Devauchelle-Pensec V, Ferlet JF, Jousse-Joulin S, D’Agostino MA, Backhaus M et al (2013) The ability of synovitis to predict structural damage in rheumatoid arthritis: a comparative study between clinical examination and ultrasound. Ann Rheum Dis 72(5):665 (http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/980/CN-00916980/frame.html.)PubMedCrossRef

77.

Østergaard M, Peterfy C, Conaghan P, McQueen F, Bird P, Ejbjerg B et al (2003) Omeract rheumatoid arthritis magnetic resonance imaging studies. Core set of mri acquisitions, joint pathology definitions, and the omeract ra-mri scoring system. J Rheumatol 30:1385–1386PubMed

78.

Baker JF, Ostergaard M, Emery P, Hsia EC, Lu J, Baker DG et al (2014) Early mri measures independently predict 1‑year and 2‑year radiographic progression in rheumatoid arthritis: Secondary analysis from a large clinical trial. Ann Rheum Dis 73(11):1968 (http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/269/CN-01122269/frame.html)PubMedCrossRef

79.

van Steenbergen HW, Aletaha D, Beaart-van de Voorde LJJ, Brouwer E, Codreanu C, Combe B et al (2017) Eular definition of arthralgia suspicious for progression to rheumatoid arthritis. Ann Rheum Dis 76:491–496PubMedCrossRef

80.

Härter M (2004) Shared decision making—from the point of view of patients, physicians and health politics is set in place. Z Arztl Fortbild Qualitatssich 98:89–92PubMed

81.

Bieber C, Gschwendtner K, Müller N, Eich W (2016) Partizipative entscheidungsfindung (pef)—patient und arzt als team. Psychother Psychosom Med Psychol 66:195–207PubMedCrossRef

82.

Loh A, Simon D, Kriston L, Härter M (2007) Patientenbeteiligung bei medizinischen entscheidungen. Dtsch Arztebl Int 104:1483

83.

Wiek DBP, Clausen J (2016) Patientenbeteiligung an forschungsprojekten: Die forschungspartner der deutschen rheuma-liga. Z Rheumatol 75:236CrossRef

84.

Allam A, Kostova Z, Nakamoto K, Schulz PJ (2015) The effect of social support features and gamification on a web-based intervention for rheumatoid arthritis patients: Randomized controlled trial. J Med Internet Res 17(1):e14 (http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/185/CN-01111185/frame.html.)PubMedPubMedCentralCrossRef

85.

Cheung PP, Lahiri M, Teng GG, Lim AY, Lau TC, Lateef A et al (2015) A randomized controlled trial for improving patient self-assessment of synovitis in rheumatoid arthritis with education by ultrasonography: the raeus study. Rheumatology 54(7):1161 (http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/087/CN-01086087/frame.html)PubMedCrossRef

86.

Fraenkel L, Matzko CK, Webb DE, Oppermann B, Charpentier P, Peters E et al (2015) Use of decision support for improved knowledge, values clarification, and informed choice in patients with rheumatoid arthritis. Arthritis Care Res 67(11):1496 (http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/736/CN-01105736/frame.html.)CrossRef

87.

Gronning K, Skomsvoll JF, Rannestad T, Steinsbekk A (2012) The effect of an educational programme consisting of group and individual arthritis education for patients with polyarthritis—a randomised controlled trial. Patient Educ Couns 88:113–120PubMedCrossRef

88.

Homer D, Nightingale P, Jobanputra P (2009) Providing patients with information about disease-modifying anti-rheumatic drugs: Individually or in groups? A pilot randomized controlled trial comparing adherence and satisfaction. Musculoskeletal Care 7(2):78 (http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/343/CN-00719343/frame.html)PubMedCrossRef

89.

John H, Hale ED, Treharne GJ, Kitas GD, Carroll D (2013) A randomized controlled trial of a cognitive behavioural patient education intervention vs a traditional information leaflet to address the cardiovascular aspects of rheumatoid disease. Rheumatology 52(1):81–90. https://doi.org/10.1093/rheumatology/kes237 (http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/527/CN-00863527/frame.html.)CrossRefPubMed

90.

Lovisi Neto BE, Jennings F, Barros Ohashi C, Silva PG, Natour J (2009) Evaluation of the efficacy of an educational program for rheumatoid arthritis patients. Clin Exp Rheumatol 27(1):28–34 (from: http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/210/CN-00705210/frame.html)PubMed

91.

Manning VL, Hurley MV, Scott DL, Coker B, Choy E, Bearne LM (2014) Education, self-management, and upper extremity exercise training in people with rheumatoid arthritis: A randomized controlled trial. Arthritis Care Res (Hoboken) 66(2):217–227. (http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/532/CN-00978532/frame.html)CrossRef

92.

Ndosi M, Johnson D, Young T, Hardware B, Hill J, Hale C et al (2016) Effects of needs-based patient education on self-efficacy and health outcomes in people with rheumatoid arthritis: a multicentre, single blind, randomised controlled trial. Ann Rheum Dis 75(6):1126–1132. (http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/404/CN-01158404/frame.html)PubMedCrossRef

93.

Niedermann K, Buchi S, Ciurea A, Kubli R, Steurer-Stey C, Villiger PM et al (2012) Six and 12 months’ effects of individual joint protection education in people with rheumatoid arthritis: a randomized controlled trial. Scand J Occup Ther 19:360–369PubMedCrossRef

94.

Pot-Vaucel M, Aubert MP, Guillot P, Glemarec J, Berthelot JM, Le Goff B et al (2016) Randomised study versus control group of customised therapeutic education for patients in follow-up for rheumatoid arthritis. Joint Bone Spine 83:199–206PubMedCrossRef

95.

Jansen LM, van der Horst-Bruinsma IE, van Schaardenburg D, Bezemer PD, Dijkmans BA (2001) Predictors of radiographic joint damage in patients with early rheumatoid arthritis. Ann Rheum Dis 60:924–927PubMedPubMedCentralCrossRef

96.

Bosello S, Fedele AL, Peluso G, Gremese E, Tolusso B, Ferraccioli G (2011) Very early rheumatoid arthritis is the major predictor of major outcomes: clinical acr remission and radiographic non-progression. Ann Rheum Dis 70:1292–1295PubMedCrossRef

97.

Egsmose C, Lund B, Borg G, Pettersson H, Berg E, Brodin U et al (1995) Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study. J Rheumatol 22:2208–2213PubMed

98.

Gremese E, Salaffi F, Bosello SL, Ciapetti A, Bobbio-Pallavicini F, Caporali R et al (2013) Very early rheumatoid arthritis as a predictor of remission: A multicentre real life prospective study. Ann Rheum Dis 72:858–862PubMedCrossRef

99.

Tsakonas E, Fitzgerald AA, Fitzcharles MA, Cividino A, Thorne JC, M’Seffar A et al (2000) Consequences of delayed therapy with second-line agents in rheumatoid arthritis: A 3 year followup on the hydroxychloroquine in early rheumatoid arthritis (hera) study. J Rheumatol 27:623–629PubMed

100.

Hua C, Daien CI, Combe B, Landewe R (2017) Diagnosis, prognosis and classification of early arthritis: results of a systematic review informing the 2016 update of the eular recommendations for the management of early arthritis. RMD Open 3:e406PubMedPubMedCentralCrossRef

101.

van der Kooij SM, de Vries-Bouwstra JK, Goekoop-Ruiterman YPM, Ewals JAPM, Han KH, Hazes JMW et al (2008) Patient-reported outcomes in a randomized trial comparing four different treatment strategies in recent-onset rheumatoid arthritis. Arthritis Care Res 61:4–12CrossRef

102.

Wiles NJ, Dunn G, Barrett EM, Harrison BJ, Silman AJ, Symmons DP (2000) One year followup variables predict disability 5 years after presentation with inflammatory polyarthritis with greater accuracy than at baseline. J Rheumatol 27:2360–2366PubMed

103.

Lard LR, Boers M, Verhoeven A, Vos K, Visser H, Hazes JMW et al (2002) Early and aggressive treatment of rheumatoid arthritis patients affects the association of hla class ii antigens with progression of joint damage. Arthritis Rheum 46:899–905PubMedCrossRef

104.

Lukas C, Combe B, Ravaud P, Sibilia J, Landew R, van der Heijde D (2011) Favorable effect of very early disease-modifying antirheumatic drug treatment on radiographic progression in early inflammatory arthritis: data from the etude et suivi des polyarthrites indifferenciees recentes (study and followup of early undifferentiated polyarthritis). Arthritis Rheum 63:1804–1811PubMedCrossRef

105.

Möttönen T, Hannonen P, Korpela M, Nissilä M, Kautiainen H, Ilonen J et al (2002) Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 46:894–898PubMedCrossRef

106.

Soderlin MK, Bergman S (2011) Absent “window of opportunity” in smokers with short disease duration. Data from barfot, a multicenter study of early rheumatoid arthritis. J Rheumatol 38:2160–2168PubMedCrossRef

107.

Monti S, Montecucco C, Bugatti S, Caporali R (2015) Rheumatoid arthritis treatment: the earlier the better to prevent joint damage. RMD Open 1:e57PubMedPubMedCentralCrossRef

108.

Markusse IM, Akdemir G, Dirven L, Goekoop-Ruiterman YP, Groenendael JH, Han KH et al (2016) Long-term outcomes of patients with recent-onset rheumatoid arthritis after 10 years of tight controlled treatment: a randomized trial. Ann Intern Med 164(8):523–531. (http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/283/CN-01153283/frame.html)PubMedCrossRef

109.

van der Woude D, Young A, Jayakumar K, Mertens BJ, Toes REM, van der Heijde D et al (2009) Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts. Arthritis Rheum 60:2262–2271PubMedCrossRef

110.

Burgers LE, Allaart CF, Huizinga TWJ, Helm-van Mil AHM (2017) Clinical trials aiming to prevent the development of rheumatoid arthritis cannot detect prevention without adequate risk stratification; a trial performed in uapatients as example. Arthritis Rheumatol 69(5):926–931 (http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/881/CN-01292881/frame.html)PubMedCrossRef

111.

van Dongen H, van Aken J, Lard LR, Visser K, Ronday HK, Hulsmans HMJ et al (2007) Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: A double-blind, randomized, placebo-controlled trial. Arthritis Rheum 56:1424–1432PubMedCrossRef

112.

Peltomaa R, Paimela L, Kautiainen H, Leirisalo-Repo M (2002) Mortality in patients with rheumatoid arthritis treated actively from the time of diagnosis. Ann Rheum Dis 61:889–894PubMedPubMedCentralCrossRef

113.

van Jaarsveld CH, Jacobs JW, van der Veen MJ, Blaauw AA, Kruize AA, Hofman DM et al (2000) Aggressive treatment in early rheumatoid arthritis: A randomised controlled trial. On behalf of the rheumatic research foundation utrecht, the netherlands. Ann Rheum Dis 59:468–477PubMedPubMedCentralCrossRef

114.

Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P et al (2016) Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 75:3–15PubMedCrossRef

115.

Möttönen T, Paimela L, Ahonen J, Helve T, Hannonen P, Leirisalo-Repo M (1996) Outcome in patients with early rheumatoid arthritis treated according to the “sawtooth” strategy. Arthritis Rheum 39:996–1005PubMedCrossRef

116.

Fries JF, Williams CA, Ramey D, Bloch DA (1993) The relative toxicity of disease-modifying antirheumatic drugs. Arthritis Rheum 36:297–306PubMedCrossRef

117.

Tijhuis GJ, Zwinderman AH, Hazes JMW, Van Den Hout WB, Breedveld FC, Vliet Vlieland TPM (2002) A randomized comparison of care provided by a clinical nurse specialist, an inpatient team, and a day patient team in rheumatoid arthritis. Arthritis Rheum 47:525–531PubMedCrossRef

118.

Vliet Vlieland TP, Zwinderman AH, Vandenbroucke JP, Breedveld FC, Hazes JM (1996) A randomized clinical trial of in-patient multidisciplinary treatment versus routine out-patient care in active rheumatoid arthritis. Br J Rheumatol 35:475–482PubMedCrossRef

119.

Vliet Vlieland TP, Breedveld FC, Hazes JM (1997) The two-year follow-up of a randomized comparison of in-patient multidisciplinary team care and routine out-patient care for active rheumatoid arthritis. Br J Rheumatol 36:82–85PubMedCrossRef

120.

Helewa A, Bombardier C, Goldsmith CH, Menchions B, Smythe HA (1989) Cost-effectiveness of inpatient and intensive outpatient treatment of rheumatoid arthritis. A randomized, controlled trial. Arthritis Rheum 32:1505–1514PubMedCrossRef

121.

Lambert CM, Hurst NP, Forbes JF, Lochhead A, Macleod M, Nuki G (1998) Is day care equivalent to inpatient care for active rheumatoid arthritis? Randomised controlled clinical and economic evaluation. BMJ 316:965–969PubMedPubMedCentralCrossRef

122.

Ayhan F (2011) Long-term effects of comprehensive inpatient rehabilitation on function and disease activity in patients with chronic rheumatoid arthritis and ankylosing spondylitis. Turk J Rheumatol 26:135–144CrossRef

123.

Bearne LM, Byrne A‑M, Segrave H, White CM (2016) Multidisciplinary team care for people with rheumatoid arthritis: a systematic review and meta-analysis. Rheumatol Int 36:311–324PubMedCrossRef

124.

van den Hout WB, Tijhuis GJ, Hazes JMW, Breedveld FC, Vliet Vlieland TPM (2003) Cost effectiveness and cost utility analysis of multidisciplinary care in patients with rheumatoid arthritis: A randomised comparison of clinical nurse specialist care, inpatient team care, and day patient team care. Ann Rheum Dis 62:308–315PubMedPubMedCentralCrossRef

125.

de Buck PDM, Schoones JW, Allaire SH, Vliet Vlieland TPM (2002) Vocational rehabilitation in patients with chronic rheumatic diseases: a systematic literature review. Semin Arthritis Rheum 32:196–203PubMedCrossRef

126.

Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J et al (2011) American college of rheumatology/european league against rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 70:404–413PubMedCrossRef

127.

Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJSM, Hazes JMW et al (2007) Comparison of treatment strategies in early rheumatoid arthritis: A randomized trial. Ann Intern Med 146:406–415PubMedCrossRef

128.

Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R et al (2004) Effect of a treatment strategy of tight control for rheumatoid arthritis (the ticora study): A single-blind randomised controlled trial. Lancet 364:263–269PubMedCrossRef

129.

Aletaha D, Funovits J, Breedveld FC, Sharp J, Segurado O, Smolen JS (2009) Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceding the period of radiographic assessment. Arthritis Rheum 60(5):1242–1249. (http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/230/CN-00700230/frame.html)PubMedCrossRef

130.

Kaneko Y, Kondo H, Takeuchi T (2013) American college of rheumatology/european league against rheumatism remission criteria for rheumatoid arthritis maintain reliable performance when evaluated in 44 joints. J Rheumatol 40:1254–1258PubMedCrossRef

131.

Lillegraven S, Prince FH, Shadick NA, Bykerk VP, Lu B, Frits ML et al (2012) Remission and radiographic outcome in rheumatoid arthritis: Application of the 2011 acr/eular remission criteria in an observational cohort. Ann Rheum Dis 71:681–686PubMedCrossRef

132.

Balsa A, de Miguel E, Castillo C, Peiteado D, Martin-Mola E (2010) Superiority of sdai over das-28 in assessment of remission in rheumatoid arthritis patients using power doppler ultrasonography as a gold standard. Rheumatology 49:683–690PubMedCrossRef

133.

Sakellariou G, Scire CA, Verstappen SM, Montecucco C, Caporali R (2013) In patients with early rheumatoid arthritis, the new acr/eular definition of remission identifies patients with persistent absence of functional disability and suppression of ultrasonographic synovitis. Ann Rheum Dis 72:245–249PubMedCrossRef

134.

Kommission bildgebende verfahren der dgrh (2007) Bildgebende verfahren in der rheumatologie. Steinkopff, Darmstadt

135.

Bijlsma JW, Welsing PM, Woodworth TG, Middelink LM, Petho-Schramm A, Bernasconi C et al (2016) Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (u-act-early): A multicentre, randomised, double-blind, double-dummy, strategy trial. Lancet 388:343–355PubMedCrossRef

136.

Dale J, Stirling A, Zhang R, Purves D, Foley J, Sambrook M et al (2016) Targeting ultrasound remission in early rheumatoid arthritis: The results of the taser study, a randomised clinical trial. Ann Rheum Dis 75(6):1043–1050. (http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/660/CN-01158660/frame.html.)PubMedCrossRef

137.

Montecucco C, Todoerti M, Sakellariou G, Scirè CA, Caporali R (2012) Low-dose oral prednisone improves clinical and ultrasonographic remission rates in early rheumatoid arthritis: Results of a 12-month open-label randomised study. Arthritis Res Ther 14(3):R112 (http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/918/CN-00864918/frame.html.)PubMedPubMedCentralCrossRef

138.

Horslev-Petersen K, Hetland ML, Junker P, Podenphant J, Ellingsen T, Ahlquist P et al (2014) Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The opera study: An investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial. Ann Rheum Dis 73:654–661PubMedCrossRef

139.

Smolen JS, Emery P, Fleischmann R, van Vollenhoven RF, Pavelka K, Durez P et al (2014) Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: The randomised controlled optima trial. Lancet 383:321–332PubMedCrossRef

140.

Nam JL, Villeneuve E, Hensor EM, Conaghan PG, Keen HI, Buch MH et al (2014) Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: A double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the idea study). Ann Rheum Dis 73(1):75–85 (http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/184/CN-00961184/frame.html)PubMedCrossRef

141.

Gøtzsche PC, Hansen M, Stoltenberg M, Svendsen A, Beier J, Faarvang KL et al (1996) Randomized, placebo controlled trial of withdrawal of slow-acting antirheumatic drugs and of observer bias in rheumatoid arthritis. Scand J Rheumatol 25:194–199PubMedCrossRef

142.

ten Wolde S, Breedveld FC, Hermans J, Vandenbroucke JP, van de Laar MA, Markusse HM et al (1996) Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis. Lancet 347:347–352PubMedCrossRef

143.

Felson DT, Anderson JJ, Meenan RF (1990) The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses. Arthritis Rheum 33:1449–1461PubMedCrossRef

144.

Sokka T, Hannonen P (1999) Utility of disease modifying antirheumatic drugs in “sawtooth” strategy. A prospective study of early rheumatoid arthritis patients up to 15 years. Ann Rheum Dis 58:618–622PubMedPubMedCentralCrossRef

145.

Capell HA, Murphy EA, Hunter JA (1991) Rheumatoid arthritis: workload and outcome over 10 years. Q J Med 79:461–476PubMed

146.

Strangfeld A, Eveslage M, Schneider M, Bergerhausen HJ, Klopsch T, Zink A et al (2011) Treatment benefit or survival of the fittest: What drives the time-dependent decrease in serious infection rates under tnf inhibition and what does this imply for the individual patient? Ann Rheum Dis 70(11):1914–1920. (http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/866/CN-00890866/frame.html.)PubMedCrossRef

147.

Norton S, Koduri G, Nikiphorou E, Dixey J, Williams P, Young A (2013) A study of baseline prevalence and cumulative incidence of comorbidity and extra-articular manifestations in ra and their impact on outcome. Rheumatology 52:99–110PubMedCrossRef

148.

Kleinert S, Krueger K (2011) Kardiovaskuläre komorbidität und ihre risikofaktoren bei rheumatoider arthritis. Z Rheumatol 70:464–472PubMedCrossRef

149.

Cavagna L, Monti S, Grosso V, Boffini N, Scorletti E, Crepaldi G et al (2013) The multifaceted aspects of interstitial lung disease in rheumatoid arthritis. Biomed Res Int 2013:759760PubMedPubMedCentralCrossRef

150.

Ogdie A, Yu Y, Haynes K, Love TJ, Maliha S, Jiang Y et al (2015) Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: A population-based cohort study. Ann Rheum Dis 74:326–332PubMedCrossRef

151.

Choy EH, Scott DL, Kingsley GH, Williams P, Wojtulewski J, Papasavvas G et al (2002) Treating rheumatoid arthritis early with disease modifying drugs reduces joint damage: A randomised double blind trial of sulphasalazine vs diclofenac sodium. Clin Exp Rheumatol 20:351–358PubMed

152.

Westhovens R, Robles M, Ximenes AC, Nayiager S, Wollenhaupt J, Durez P et al (2009) Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis 68:1870–1877PubMedCrossRef

153.

Emery P, Burmester GR, Bykerk VP, Combe BG, Furst DE, Barré E et al (2015) Evaluating drug-free remission with abatacept in early rheumatoid arthritis: Results from the phase 3b, multicentre, randomised, active-controlled avert study of 24 months, with a 12-month, double-blind treatment period. Ann Rheum Dis 74:19–26PubMedCrossRef

154.

Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R et al (2006) The premier study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54:26–37PubMedCrossRef

155.

Bejarano V, Quinn M, Conaghan PG, Reece R, Keenan A‑M, Walker D et al (2008) Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis Rheum 59:1467–1474PubMedCrossRef

156.

Takeuchi T, Yamanaka H, Ishiguro N, Miyasaka N, Mukai M, Matsubara T et al (2014) Adalimumab, a human anti-tnf monoclonal antibody, outcome study for the prevention of joint damage in japanese patients with early rheumatoid arthritis: The hopeful 1 study. Ann Rheum Dis 73:536–543PubMedCrossRef

157.

Atsumi T, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y et al (2016) The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, c‑opera, shows inhibition of radiographic progression. Ann Rheum Dis 75(1):75–83 (http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/323/CN-01134323/frame.html)PubMedCrossRef

158.

Emery P, Bingham CO, Burmester GR, Bykerk VP, Furst DE, Mariette X et al (2017) Certolizumab pegol in combination with dose-optimised methotrexate in dmard-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1‑year results from c‑early, a randomised, double-blind, placebo-controlled phase iii study. Ann Rheum Dis 76:96–104PubMedCrossRef

159.

Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC et al (2000) A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 343:1586–1593PubMedCrossRef

160.

Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D et al (2008) Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (comet): A randomised, double-blind, parallel treatment trial. Lancet 372:375–382PubMedCrossRef

161.

Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P et al (2009) Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase iii, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 60:2272–2283PubMedCrossRef

162.

St Clair EW, van der Heijde DMFM, Smolen JS, Maini RN, Bathon JM, Emery P et al (2004) Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50:3432–3443PubMedCrossRef

163.

Tak PP, Rigby WF, Rubbert-Roth A, Peterfy CG, Vollenhoven RF, Stohl W et al (2011) Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the image trial. Ann Rheum Dis 70(1):39–46 (http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/054/CN-00779054/frame.html.)PubMedCrossRef

164.

Burmester GR, Rigby WF, van Vollenhoven RF, Kay J, Rubbert-Roth A, Kelman A et al (2016) Tocilizumab in early progressive rheumatoid arthritis: function, a randomised controlled trial. Ann Rheum Dis 75:1081–1091PubMedCrossRef

165.

Hetland ML, Stengaard-Pedersen K, Junker P, Lottenburger T, Ellingsen T, Andersen LS et al (2006) Combination treatment with methotrexate, cyclosporine, and intraarticular betamethasone compared with methotrexate and intraarticular betamethasone in early active rheumatoid arthritis: An investigator-initiated, multicenter, randomized, double-blind, parallel-group, placebo-controlled study. Arthritis Rheum 54:1401–1409PubMedCrossRef

166.

Hetland ML, Stengaard-Pedersen K, Junker P, Lottenburger T, Hansen I, Andersen LS et al (2008) Aggressive combination therapy with intra-articular glucocorticoid injections and conventional disease-modifying anti-rheumatic drugs in early rheumatoid arthritis: Second-year clinical and radiographic results from the cimestra study. Ann Rheum Dis 67:815–822PubMedCrossRef

167.

van der Heijde DM, van Riel PL, Nuver-Zwart IH, Gribnau FW, vad de Putte LB (1989) Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1:1036–1038PubMedCrossRef

168.

Möttönen T, Hannonen P, Leirisalo-Repo M, Nissilä M, Kautiainen H, Korpela M et al (1999) Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: A randomised trial. Fin-raco trial group. Lancet 353:1568–1573PubMedCrossRef

169.

Landewé RB, Goei Thè HS, van Rijthoven AW, Breedveld FC, Dijkmans BA (1994) A randomized, double-blind, 24-week controlled study of low-dose cyclosporine versus chloroquine for early rheumatoid arthritis. Arthritis Rheum 37:637–643PubMedCrossRef

170.

Proudman SM, Conaghan PG, Richardson C, Griffiths B, Green MJ, McGonagle D et al (2000) Treatment of poor-prognosis early rheumatoid arthritis. A randomized study of treatment with methotrexate, cyclosporin a, and intraarticular corticosteroids compared with sulfasalazine alone. Arthritis Rheum 43:1809–1819PubMedCrossRef

171.

Haagsma CJ, van Riel PL, de Jong AJ, van de Putte LB (1997) Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: A randomized, controlled, double-blind, 52 week clinical trial. Br J Rheumatol 36:1082–1088PubMedCrossRef

172.

Dougados M, Combe B, Cantagrel A, Goupille P, Olive P, Schattenkirchner M et al (1999) Combination therapy in early rheumatoid arthritis: A randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis 58:220–225PubMedPubMedCentralCrossRef

173.

Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC et al (1997) Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 350:309–318PubMedCrossRef

174.

van Vollenhoven RF, Ernestam S, Geborek P, Petersson IF, Cöster L, Waltbrand E et al (2009) Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (swefot trial): 1‑year results of a randomised trial. Lancet 374:459–466PubMedCrossRef

175.

Hannonen P, Möttönen T, Hakola M, Oka M (1993) Sulfasalazine in early rheumatoid arthritis. A 48-week double-blind, prospective, placebo-controlled study. Arthritis Rheum 36:1501–1509PubMedCrossRef

176.

Fleischmann R, Schiff M, van der Heijde D, Ramos-Remus C, Spindler A, Stanislav M et al (2017) Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheumatol 69:506–517PubMedPubMedCentralCrossRef

177.

Fleischmann RM, Huizinga TWJ, Kavanaugh AF, Wilkinson B, Kwok K, DeMasi R et al (2016) Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis. RMD Open 2:e262PubMedPubMedCentralCrossRef

178.

Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley JD, Gruben D et al (2014) Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 370:2377–2386PubMedCrossRef

179.

Clark P, Tugwell P, Bennet K, Bombardier C, Shea B, Wells G et al (2000) Injectable gold for rheumatoid arthritis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD000520 CrossRefPubMed

180.

Suarez-Almazor ME, Belseck E, Shea B, Homik J, Wells G, Tugwell P (2000) Antimalarials for treating rheumatoid arthritis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD000959 CrossRefPubMedPubMedCentral

181.

Suarez-Almazor ME, Belseck E, Shea B, Wells G, Tugwell P (2000) Methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD000957 CrossRefPubMedPubMedCentral

182.

Suarez-Almazor ME, Belseck E, Shea B, Wells G, Tugwell P (2000) Sulfasalazine for rheumatoid arthritis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD000958 CrossRefPubMedPubMedCentral

183.

Suarez-Almazor ME, Spooner C, Belseck E (2000) Azathioprine for treating rheumatoid arthritis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD001461 CrossRefPubMedPubMedCentral

184.

Suarez-Almazor ME, Spooner C, Belseck E (2000) Penicillamine for treating rheumatoid arthritis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD001460 CrossRefPubMedPubMedCentral

185.

Suarez-Almazor ME, Spooner CH, Belseck E, Shea B (2000) Auranofin versus placebo in rheumatoid arthritis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD002048 CrossRefPubMedPubMedCentral

186.

Wells G, Haguenauer D, Shea B, Suarez-Almazor ME, Welch VA, Tugwell P (2000) Cyclosporine for rheumatoid arthritis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD001083 CrossRefPubMedPubMedCentral

187.

Fries JF, Williams CA, Morfeld D, Singh G, Sibley J (1996) Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies. Arthritis Rheum 39:616–622PubMedCrossRef

188.

Choi HK, Hernán MA, Seeger JD, Robins JM, Wolfe F (2002) Methotrexate and mortality in patients with rheumatoid arthritis: A prospective study. Lancet 359:1173–1177PubMedCrossRef

189.

Krause D, Schleusser B, Herborn G, Rau R (2000) Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis Rheum 43:14–21PubMedCrossRef

190.

Ferraccioli GF, Gremese E, Tomietto P, Favret G, Damato R, Di Poi E (2002) Analysis of improvements, full responses, remission and toxicity in rheumatoid patients treated with step-up combination therapy (methotrexate, cyclosporin a, sulphasalazine) or monotherapy for three years. Rheumatology 41:892–898PubMedCrossRef

191.

Menninger H, Herborn G, Sander O, Blechschmidt J, Rau R (1998) A 36 month comparative trial of methotrexate and gold sodium thiomalate in the treatment of early active and erosive rheumatoid arthritis. Br J Rheumatol 37:1060–1068PubMedCrossRef

192.

Rau R, Herborn G, Menninger H, Sangha O (2002) Radiographic outcome after three years of patients with early erosive rheumatoid arthritis treated with intramuscular methotrexate or parenteral gold. Extension of a one-year double-blind study in 174 patients. Rheumatology 41:196–204PubMedCrossRef

193.

Verschueren P, De Cock D, Corluy L, Joos R, Langenaken C, Taelman V et al (2017) Effectiveness of methotrexate with step-down glucocorticoid remission induction (cobra slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1‑year results of carera, a randomised pragmatic open-label superiority trial. Ann Rheum Dis 76:511–520PubMedCrossRef

194.

Emery P, Breedveld FC, Lemmel EM, Kaltwasser JP, Dawes PT, Gömör B et al (2000) A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology 39:655–665PubMedCrossRef

195.

Kremer JM, Genovese MC, Cannon GW, Caldwell JR, Cush JJ, Furst DE et al (2002) Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 137:726–733PubMedCrossRef

196.

Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A et al (1999) Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: A double-blind, randomised, multicentre trial. European leflunomide study group. Lancet 353:259–266PubMedCrossRef

197.

Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G et al (1999) Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide rheumatoid arthritis investigators group. Arch Intern Med 159:2542–2550PubMedCrossRef

198.

Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH et al (2002) Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two-year radiographic and clinical outcomes. Arthritis Rheum 46:1443–1450PubMedCrossRef

199.

Kimel M, Cifaldi M, Chen N, Revicki D (2008) Adalimumab plus methotrexate improved sf-36 scores and reduced the effect of rheumatoid arthritis (ra) on work activity for patients with early ra. J Rheumatol 35:206–215PubMed

200.

Donahue KE, Gartlehner G, Jonas DE, Lux LJ, Thieda P, Jonas BL et al (2008) Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 148:124–134PubMedCrossRef

201.

Sarzi-Puttini P, D’Ingianna E, Fumagalli M, Scarpellini M, Fiorini T, Cherie-Ligniere EL et al (2005) An open, randomized comparison study of cyclosporine a, cyclosporine a + methotrexate and cyclosporine a + hydroxychloroquine in the treatment of early severe rheumatoid arthritis. Rheumatol Int 25:15–22PubMedCrossRef

202.

Gerards AH, Landewé RBM, Prins APA, Bruyn GW, Goei Thé HS, Laan RFJM et al (2003) Cyclosporin a monotherapy versus cyclosporin a and methotrexate combination therapy in patients with early rheumatoid arthritis: a double blind randomised placebo controlled trial. Ann Rheum Dis 62:291–296PubMedPubMedCentralCrossRef

203.

Marchesoni A, Battafarano N, Arreghini M, Panni B, Gallazzi M, Tosi S (2003) Radiographic progression in early rheumatoid arthritis: A 12-month randomized controlled study comparing the combination of cyclosporin and methotrexate with methotrexate alone. Rheumatology 42:1545–1549PubMedCrossRef

204.

Durez P, Malghem J, Nzeusseu Toukap A, Depresseux G, Lauwerys BR, Westhovens R et al (2007) Treatment of early rheumatoid arthritis: A randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone. Arthritis Rheum 56:3919–3927PubMedCrossRef

205.

Smolen JS, Han C, van der Heijde D, Emery P, Bathon JM, Keystone E et al (2006) Infliximab treatment maintains employability in patients with early rheumatoid arthritis. Arthritis Rheum 54:716–722PubMedCrossRef

206.

Kekow J, Moots RJ, Emery P, Durez P, Koenig A, Singh A et al (2010) Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: The comet trial. Ann Rheum Dis 69:222–225PubMedCrossRef

207.

Ma MH, Kingsley GH, Scott DL (2010) A systematic comparison of combination dmard therapy and tumour necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritis. Rheumatology 49:91–98PubMedCrossRef

208.

Katchamart W, Trudeau J, Phumethum V, Bombardier C (2009) Efficacy and toxicity of methotrexate (mtx) monotherapy versus mtx combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: A systematic review and meta-analysis. Ann Rheum Dis 68:1105–1112PubMedCrossRef

209.

Singh JA, Hossain A, Tanjong Ghogomu E, Kotb A, Christensen R, Mudano AS et al (2016) Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: A systematic review and network meta-analysis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD012183 CrossRefPubMedPubMedCentral

210.

Saunders SA, Capell HA, Stirling A, Vallance R, Kincaid W, McMahon AD et al (2008) Triple therapy in early active rheumatoid arthritis: A randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies. Arthritis Rheum 58:1310–1317PubMedCrossRef

211.

Capell HA, Madhok R, Porter DR, Munro RA, McInnes IB, Hunter JA et al (2007) Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled mascot study. Ann Rheum Dis 66:235–241PubMedCrossRef

212.

Choy EH, Smith CM, Farewell V, Walker D, Hassell A, Chau L et al (2008) Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis. Ann Rheum Dis 67:656–663PubMedCrossRef

213.

Le Loet X, Berthelot JM, Cantagrel A, Combe B, De Bandt M, Fautrel B et al (2006) Clinical practice decision tree for the choice of the first disease modifying antirheumatic drug for very early rheumatoid arthritis: A 2004 proposal of the french society of rheumatology. Ann Rheum Dis 65:45–50PubMedCrossRef

214.

Lopez-Olivo Maria A, Siddhanamatha Harish R, Shea B, Tugwell P, Wells GA, Suarez-Almazor ME (2014) Methotrexate for treating rheumatoid arthritis. Cochrane Database Syst Rev 2014(6):CD000957 (http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD000957.pub2/abstract)PubMedCentral

215.

Hider SL, Silman A, Bunn D, Manning S, Symmons D, Lunt M (2006) Comparing the long-term clinical outcome of treatment with methotrexate or sulfasalazine prescribed as the first disease-modifying antirheumatic drug in patients with inflammatory polyarthritis. Ann Rheum Dis 65:1449–1455PubMedPubMedCentralCrossRef

216.

Fiehn C, Holle J, Iking-Konert C, Leipe J, Weseloh C, Frerix M et al (2018) S2e-leitlinie: Therapie der rheumatoiden arthritis mit krankheitsmodifizierenden medikamenten. Z Rheumatol 77:35–53PubMedCrossRef

217.

Felson DT, Anderson JJ, Meenan RF (1992) Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials. Arthritis Rheum 35:1117–1125PubMedCrossRef

218.

van Ede AE, Laan RF, Rood MJ, Huizinga TW, van de Laar MA, van Denderen CJ et al (2001) Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: A forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 44:1515–1524PubMedCrossRef

219.

Shea B, Swinden Michael V, Tanjong Ghogomu E, Ortiz Z, Katchamart W, Rader T et al (2013) Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev 2013(5):CD000951 (http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD000951.pub2/abstract.)PubMedCentral

220.

Alfaro-Lara R, Espinosa-Ortega HF, Arce-Salinas CA (2017) Systematic review and meta-analysis of the efficacy and safety of leflunomide and methotrexate in the treatment of rheumatoid arthritis. Reumatol Clin 15(3):133–139PubMedCrossRef

221.

Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V (2006) Anti-tnf antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295:2275–2285PubMedCrossRef

222.

Ramiro S, Sepriano A, Chatzidionysiou K, Nam JL, Smolen JS, van der Heijde D et al (2017) Safety of synthetic and biological dmards: A systematic literature review informing the 2016 update of the eular recommendations for management of rheumatoid arthritis. Ann Rheum Dis 76:1101–1136PubMedCrossRef

223.

Strangfeld A, Richter A, Siegmund B, Herzer P, Rockwitz K, Demary W et al (2017) Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic dmards. Ann Rheum Dis 76:504–510PubMedCrossRef

224.

Krüger K, Albrecht K, Rehart S, Scholz R, der Kommission Pharmakotherapie D (2014) Recommendations of the german society for rheumatology on the perioperative approach under therapy with dmards and biologicals in inflammatory rheumatic diseases. Z Rheumatol 73:77–84PubMedCrossRef

225.

Asten P, Barrett J, Symmons D (1999) Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases. J Rheumatol 26:1705–1714PubMed

226.

Baecklund E, Ekbom A, Sparén P, Feltelius N, Klareskog L (1998) Disease activity and risk of lymphoma in patients with rheumatoid arthritis: Nested case-control study. BMJ 317:180–181PubMedPubMedCentralCrossRef

227.

Beauparlant P, Papp K, Haraoui B (1999) The incidence of cancer associated with the treatment of rheumatoid arthritis. Semin Arthritis Rheum 29:148–158PubMedCrossRef

228.

Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F et al (2006) Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 54:692–701PubMedCrossRef

229.

Maneiro JR, Souto A, Gomez-Reino JJ (2017) Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, meta-analysis, and network meta-analysis. Semin Arthritis Rheum 47:149–156PubMedCrossRef

230.

Askling J, van Vollenhoven RF, Granath F, Raaschou P, Fored CM, Baecklund E et al (2009) Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: Does the risk change with the time since start of treatment? Arthritis Rheum 60:3180–3189PubMedCrossRef

231.

Wadström H, Frisell T, Askling J, The Anti-Rheumatic Therapy in Sweden Study G (2017) Malignant neoplasms in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, tocilizumab, abatacept, or rituximab in clinical practice: A nationwide cohort study from sweden. JAMA Intern Med 177:1605PubMedPubMedCentralCrossRef

232.

Laan RF, Jansen TL, van Riel PL (1999) Glucocorticosteroids in the management of rheumatoid arthritis. Rheumatology 38:6–12PubMedCrossRef

233.

Gotzsche PC, Johansen HK (1998) Meta-analysis of short-term low dose prednisolone versus placebo and non-steroidal anti-inflammatory drugs in rheumatoid arthritis. BMJ 316:811–818PubMedPubMedCentralCrossRef

234.

Gotzsche PC, Johansen HK (2003) Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD000189 CrossRefPubMedPubMedCentral

235.

ter Wee MM, den Uyl D, Boers M, Kerstens P, Nurmohamed M, van Schaardenburg D et al (2015) Intensive combination treatment regimens, including prednisolone, are effective in treating patients with early rheumatoid arthritis regardless of additional etanercept: 1‑year results of the cobra-light open-label, randomised, non-inferiority trial. Ann Rheum Dis 74:1233–1240PubMed

236.

Buttgereit F, Doering G, Schaeffler A, Witte S, Sierakowski S, Gromnica-Ihle E et al (2008) Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (capra-1): A double-blind, randomised controlled trial. Lancet 371:205–214PubMedCrossRef

237.

Gestel AMV, Laan RFJM, Haagsma CJ, Van De Putte LBA, Van Riel PLCM (1995) Oral steroids as bridge therapy in rheumatoid arthritis patients starting with parenteral gold. A randomized double-blind placebo-controlled trial. Baillieres Clin Rheumatol 34:347–351

238.

Million R, Kellgren JH, Poole P, Jayson MI (1984) Long-term study of management of rheumatoid arthritis. Lancet 1:812–816PubMedCrossRef

239.

Kirwan JR, Reeback JS (1986) Stanford health assessment questionnaire modified to assess disability in british patients with rheumatoid arthritis. Br J Rheumatol 25:206–209PubMedCrossRef

240.

Kirwan JR (1995) The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The arthritis and rheumatism council low-dose glucocorticoid study group. N Engl J Med 333:142–146PubMedCrossRef

241.

Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M et al (2017) Eular recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76:960–977PubMedCrossRef

242.

Hickling P, Jacoby RK, Kirwan JR (1998) Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Arthritis and rheumatism council low dose glucocorticoid study group. Br J Rheumatol 37:930–936PubMedCrossRef

243.

Kirwan JR, Bijlsma JW, Boers M, Shea BJ (2007) Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD006356 CrossRefPubMedPubMedCentral

244.

van Everdingen AA, Jacobs JW, Siewertsz Van Reesema DR, Bijlsma JW (2002) Low-dose prednisone therapy for patients with early active rheumatoid arthritis: Clinical efficacy, disease-modifying properties, and side effects: A randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med 136:1–12PubMedCrossRef

245.

Bakker MF, Jacobs JW, Welsing PM, Verstappen SM, Tekstra J, Ton E et al (2012) Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med 156:329–339PubMedCrossRef

246.

McDougall R, Sibley J, Haga M, Russell A (1994) Outcome in patients with rheumatoid arthritis receiving prednisone compared to matched controls. J Rheumatol 21:1207–1213PubMed

247.

Saag KG (1997) Low-dose corticosteroid therapy in rheumatoid arthritis: Balancing the evidence. Am J Med 103:31S–39SPubMedCrossRef

248.

Saag KG, Koehnke R, Caldwell JR, Brasington R, Burmeister LF, Zimmerman B et al (1994) Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 96:115–123PubMedCrossRef

249.

Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA et al (1994) The mortality of rheumatoid arthritis. Arthritis Rheum 37:481–494PubMedCrossRef

250.

Strehl C, Bijlsma JW, de Wit M, Boers M, Caeyers N, Cutolo M et al (2016) Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: Viewpoints from an eular task force. Ann Rheum Dis 75:952–957PubMedCrossRef

251.

Seror P, Pluvinage P, d’Andre FL, Benamou P, Attuil G (1999) Frequency of sepsis after local corticosteroid injection (an inquiry on 1160000 injections in rheumatological private practice in france). Rheumatology 38:1272–1274PubMedCrossRef

252.

Weitoft T, Uddenfeldt P (2000) Importance of synovial fluid aspiration when injecting intra-articular corticosteroids. Ann Rheum Dis 59:233–235PubMedPubMedCentralCrossRef

253.

Chakravarty K, Pharoah PD, Scott DG (1994) A randomized controlled study of post-injection rest following intra-articular steroid therapy for knee synovitis. Br J Rheumatol 33:464–468PubMedCrossRef

254.

Wallen M, Gillies D (2006) Intra-articular steroids and splints/rest for children with juvenile idiopathic arthritis and adults with rheumatoid arthritis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD002824.pub2 CrossRefPubMedPubMedCentral

255.

Brooks PM, Day RO (1991) Nonsteroidal antiinflammatory drugs—differences and similarities. N Engl J Med 324:1716–1725PubMedCrossRef

256.

Furst DE (1994) Are there differences among nonsteroidal antiinflammatory drugs? Comparing acetylated salicylates, nonacetylated salicylates, and nonacetylated nonsteroidal antiinflammatory drugs. Arthritis Rheum 37:1–9PubMedCrossRef

257.

van Walsem A, Pandhi S, Nixon RM, Guyot P, Karabis A, Moore RA (2015) Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase‑2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: A network meta-analysis. Arthritis Res Ther 17:66PubMedPubMedCentralCrossRef

258.

Colebatch AN, Marks JL, Edwards CJ (2011) Safety of non-steroidal anti-inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people receiving methotrexate for inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis). Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD008872.pub2 CrossRefPubMed

259.

Nsaids GPC (2010) BMJ clinical evidence 2010

260.

Hardin JG Jr., Kirk KA (1979) Comparative effectiveness of five analgesics for the pain of rheumatoid synovitis. J Rheumatol 6:405–412PubMed

261.

Huskisson EC (1974) Simple analgesics for arthritis. Br Med J 4:196–200PubMedPubMedCentralCrossRef

262.

Seideman P, Melander A (1988) Equianalgesic effects of paracetamol and indomethacin in rheumatoid arthritis. Br J Rheumatol 27:117–122PubMedCrossRef

263.

Wienecke T, Gotzsche PC (2004) Paracetamol versus nonsteroidal anti-inflammatory drugs for rheumatoid arthritis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD003789.pub2 CrossRefPubMedPubMedCentral

264.

Moore RA, Derry S, Wiffen PJ, Straube S, Aldington DJ (2015) Overview review: Comparative efficacy of oral ibuprofen and paracetamol (acetaminophen) across acute and chronic pain conditions. Eur J Pain 19:1213–1223PubMedCrossRef

265.

Whittle S, Richards B, Buchbinder R (2011) The efficacy and safety of opioids in rheumatoid arthritis: A cochrane systematic review. Cochrane Database Syst Rev 41(11):CD003113 (http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/419/CN-01003419/frame.html.)

266.

Chandanwale AS, Sundar S, Latchoumibady K, Biswas S, Gabhane M, Naik M et al (2014) Efficacy and safety profile of combination of tramadol-diclofenac versus tramadol-paracetamol in patients with acute musculoskeletal conditions, postoperative pain, and acute flare of osteoarthritis and rheumatoid arthritis: A phase iii, 5‑day open-label study. J Pain Res 7:455–463. (http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/394/CN-01002394/frame.html.)PubMedPubMedCentral

267.

Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E (2006) Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. CMAJ 174:1589–1594PubMedPubMedCentralCrossRef

268.

Bell MJ, Lineker SC, Wilkins AL, Goldsmith CH, Badley EM (1998) A randomized controlled trial to evaluate the efficacy of community based physical therapy in the treatment of people with rheumatoid arthritis. J Rheumatol 25:231–237PubMed

269.

Mayoux Benhamou MA (2007) Reconditioning in patients with rheumatoid arthritis. Ann Readapt Med Phys 50:382–5, 77–81PubMedCrossRef

270.

Metsios GS, Stavropoulos-Kalinoglou A, Veldhuijzen van Zanten JJ, Treharne GJ, Panoulas VF, Douglas KM et al (2008) Rheumatoid arthritis, cardiovascular disease and physical exercise: a systematic review. Rheumatology 47:239–248PubMedCrossRef

271.

Neill J, Belan I, Ried K (2006) Effectiveness of non-pharmacological interventions for fatigue in adults with multiple sclerosis, rheumatoid arthritis, or systemic lupus erythematosus: A systematic review. J Adv Nurs 56:617–635PubMedCrossRef

272.

Wessel J (2004) The effectiveness of hand exercises for persons with rheumatoid arthritis: a systematic review. J Hand Ther 17:174–180PubMedCrossRef

273.

Eversden L, Maggs F, Nightingale P, Jobanputra P (2007) A pragmatic randomised controlled trial of hydrotherapy and land exercises on overall well being and quality of life in rheumatoid arthritis. BMC Musculoskelet Disord 8:23PubMedPubMedCentralCrossRef

274.

Baillet A, Vaillant M, Guinot M, Juvin R, Gaudin P (2012) Efficacy of resistance exercises in rheumatoid arthritis: Meta-analysis of randomized controlled trials (structured abstract). Rheumatology (Oxford) 51(3):519–527. (http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012014201/frame.html.)CrossRef

275.

Baillet A, Zeboulon N, Gossec L, Combescure C, Bodin LA, Juvin R et al (2010) Efficacy of cardiorespiratory aerobic exercise in rheumatoid arthritis: meta-analysis of randomized controlled trials. Arthritis Care Res 62:984–992CrossRef

276.

Bulthuis Y, Drossaers-Bakker KW, Taal E, Rasker J, Oostveen J, van’t Pad Bosch P et al (2007) Arthritis patients show long-term benefits from 3 weeks intensive exercise training directly following hospital discharge. Baillieres Clin Rheumatol 46:1712–1717

277.

Bulthuis Y, Mohammad S, Braakman-Jansen LM, Drossaers-Bakker KW, van de Laar MA (2008) Cost-effectiveness of intensive exercise therapy directly following hospital discharge in patients with arthritis: Results of a randomized controlled clinical trial. Arthritis Rheum 59:247–254PubMedCrossRef

278.

Gaudin P, Leguen-Guegan S, Allenet B, Baillet A, Grange L, Juvin R (2008) Is dynamic exercise beneficial in patients with rheumatoid arthritis? Joint Bone Spine 75:11–17PubMedCrossRef

279.

Neuberger GB, Aaronson LS, Gajewski B, Embretson SE, Cagle PE, Loudon JK et al (2007) Predictors of exercise and effects of exercise on symptoms, function, aerobic fitness, and disease outcomes of rheumatoid arthritis. Arthritis Rheum 57:943–952PubMedCrossRef

280.

Plasqui G (2008) The role of physical activity in rheumatoid arthritis. Physiol Behav 94:270–275PubMedCrossRef

281.

Cairns AP, McVeigh JG (2009) A systematic review of the effects of dynamic exercise in rheumatoid arthritis. Rheumatol Int 30:147–158PubMedCrossRef

282.

Hsieh LF, Chen SC, Chuang CC, Chai HM, Chen WS, He YC (2009) Supervised aerobic exercise is more effective than home aerobic exercise in female chinese patients with rheumatoid arthritis. J Rehabil Med 41:332–337PubMedCrossRef

283.

Hurkmans E, van der Giesen FJ, Vliet Vlieland TPM, Schoones J, Van den Ende Els CHM (2009) Dynamic exercise programs (aerobic capacity and/or muscle strength training) in patients with rheumatoid arthritis. Cochrane Database Syst Rev 2009 (4):CD006853. https://doi.org/10.1002/14651858.CD006853.pub2

284.

Balsamo S, Diniz LR, dos Santos-Neto LL, da Mota LM (2014) Exercise and fatigue in rheumatoid arthritis. Isr Med Assoc J 16:57–60PubMed

285.

Cramp F, Berry J, Gardiner M, Smith F, Stephens D (2013) Health behaviour change interventions for the promotion of physical activity in rheumatoid arthritis: A systematic review. Musculoskelet Care 11:238–247CrossRef

286.

Durcan L, Wilson F, Cunnane G (2014) The effect of exercise on sleep and fatigue in rheumatoid arthritis: a randomised controlled study. J Rheumatol 41(10):1966–1973. (http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/040/CN-01050040/frame.html)

287.

Feldthusen C, Dean E, Forsblad-d’Elia H, Mannerkorpi K (2016) Effects of person-centered physical therapy on fatigue-related variables in persons with rheumatoid arthritis: A randomized controlled trial. Arch Phys Med Rehabil 97(1):26–36 (http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/299/CN-01133299/frame.html.)PubMedCrossRef

288.

de Jong Z, Munneke M, Zwinderman AH, Kroon HM, Jansen A, Ronday KH et al (2003) Is a long-term high-intensity exercise program effective and safe in patients with rheumatoid arthritis? Results of a randomized controlled trial. Arthritis Rheum 48:2415–2424PubMedCrossRef

289.

van den Berg MH, Ronday HK, Peeters AJ, le Cessie S, van der Giesen FJ, Breedveld FC et al (2006) Using internet technology to deliver a home-based physical activity intervention for patients with rheumatoid arthritis: a randomized controlled trial. Arthritis Rheum 55:935–945PubMedCrossRef

290.

Santos I, Cantista P, Vasconcelos C, Amado J (2016) Balneotherapy and rheumatoid arthritis: a randomized control trial. Int J Biometeorol 60(8):1287–1301. (http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/620/CN-01211620/frame.html)PubMedCrossRef

291.

Verhagen AP, Bierma-Zeinstra SM, Boers M, Cardoso JR, Lambeck J, De Bie R et al (2015) Balneotherapy (or spa therapy) for rheumatoid arthritis. An abridged version of cochrane systematic review. Eur J Phys Rehabil Med 51:833–847PubMed

292.

Field T, Diego M, Delgado J, Garcia D, Funk CG (2013) Rheumatoid arthritis in upper limbs benefits from moderate pressure massage therapy. Complement Ther Clin Pract 19(2):101–103. (http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/678/CN-00913678/frame.html.)PubMedCrossRef

293.

Robinson V, Brosseau L, Casimiro L, Judd M, Shea B, Wells G et al (2002) Thermotherapy for treating rheumatoid arthritis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD002826 CrossRefPubMedPubMedCentral

294.

Hirvonen HE, Mikkelsson MK, Kautiainen H, Pohjolainen TH, Leirisalo-Repo M (2006) Effectiveness of different cryotherapies on pain and disease activity in active rheumatoid arthritis. A randomised single blinded controlled trial. Clin Exp Rheumatol 24:295–301PubMed

295.

Brosseau L, Judd MG, Marchand S, Robinson VA, Tugwell P, Wells G et al (2003) Transcutaneous electrical nerve stimulation (tens) for the treatment of rheumatoid arthritis in the hand. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD004287 CrossRefPubMedPubMedCentral

296.

Brosseau L, Robinson V, Wells G, Debie R, Gam A, Harman K et al (2005) Low level laser therapy (classes i, ii and iii) for treating rheumatoid arthritis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD002049.pub2 CrossRefPubMedPubMedCentral

297.

Meireles SM, Jones A, Jennings F, Suda AL, Parizotto NA, Natour J (2010) Assessment of the effectiveness of low-level laser therapy on the hands of patients with rheumatoid arthritis: A randomized double-blind controlled trial. Clin Rheumatol 29:501–509PubMedCrossRef

298.

Casimiro L, Brosseau L, Robinson V, Milne S, Judd M, Well G et al (2002) Therapeutic ultrasound for the treatment of rheumatoid arthritis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD003787 CrossRefPubMedPubMedCentral

299.

Kelley GA, Kelley KS, Hootman JM, Jones DL (2011) Effects of community-deliverable exercise on pain and physical function in adults with arthritis and other rheumatic diseases: A meta-analysis (structured abstract). Arthritis Care Res (Hoboken) 63(1):79–93 (http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12011001218/frame.html.)CrossRef

300.

Evans S, Moieni M, Lung K, Tsao J, Sternlieb B, Taylor M et al (2013) Impact of iyengar yoga on quality of life in young women with rheumatoid arthritis. Clin J Pain 29:988–997PubMedPubMedCentralCrossRef

301.

Moonaz SH, Bingham CO, Wissow L, Bartlett SJ (2015) Yoga in sedentary adults with arthritis: Effects of a randomized controlled pragmatic trial. J Rheumatol 42(7):1194–1202. (http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/993/CN-01097993/frame.html)PubMedPubMedCentralCrossRef

302.

Singh VK, Bhandari RB, Rana BB (2011) Effect of yogic package on rheumatoid arthritis. Indian J Physiol Pharmacol 55(4):329–335. (http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/470/CN-00868470/frame.html)PubMed

303.

Han A, Robinson V, Judd M, Taixiang W, Wells G, Tugwell P (2004) Tai chi for treating rheumatoid arthritis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD004849 CrossRefPubMed

304.

Lee MS, Pittler MH, Ernst E (2007) Tai chi for rheumatoid arthritis: Systematic review. Rheumatology 46:1648–1651PubMedCrossRef

305.

Steultjens EM, Dekker J, Bouter LM, Leemrijse CJ, van den Ende CH (2005) Evidence of the efficacy of occupational therapy in different conditions: an overview of systematic reviews. Clin Rehabil 19:247–254PubMedCrossRef

306.

Steultjens EM, Dekker J, Bouter LM, van Schaardenburg D, van Kuyk MA, van den Ende CH (2002) Occupational therapy for rheumatoid arthritis: a systematic review. Arthritis Rheum 47:672–685PubMedCrossRef

307.

Lamb SE, Williamson EM, Heine PJ, Adams J, Dosanjh S, Dritsaki M et al (2015) Exercises to improve function of the rheumatoid hand (sarah): A randomised controlled trial. Lancet 385:421–429PubMedCrossRef

308.

Cima SR, Barone A, Porto JM, Abreu DCC (2013) Strengthening exercises to improve hand strength and functionality in rheumatoid arthritis with hand deformities: A randomized, controlled trial. Rheumatol Int 33(3):725–732 (http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/754/CN-00904754/frame.html.)PubMedCrossRef

309.

Dogu B, Sirzai H, Yilmaz F, Polat B, Kuran B (2013) Effects of isotonic and isometric hand exercises on pain, hand functions, dexterity and quality of life in women with rheumatoid arthritis. Rheumatol Int 33(10):2625–2630. (http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/877/CN-00913877/frame.html)PubMedCrossRef

310.

Egan M, Brosseau L, Farmer M, Ouimet MA, Rees S, Wells G et al (2003) Splints/orthoses in the treatment of rheumatoid arthritis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD004018 CrossRef

311.

Baldwin D, Johnstone B, Ge B, Hewett J, Smith M, Sharp G (2012) Randomized prospective study of a work place ergonomic intervention for individuals with rheumatoid arthritis and osteoarthritis. Arthritis Care Res 64:1527–1535CrossRef

312.

Macedo AM, Oakley SP, Panayi GS, Kirkham BW (2009) Functional and work outcomes improve in patients with rheumatoid arthritis who receive targeted, comprehensive occupational therapy. Arthritis Rheum 61(11):1522–1530. (http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/390/CN-00728390/frame.html)PubMedCrossRef

313.

Conceicao CS, Gomes Neto M, Mendes SM, Sa KN, Baptista AF (2015) Systematic review and meta-analysis of effects of foot orthoses on pain and disability in rheumatoid arthritis patients. Disabil Rehabil 37:1209–1213CrossRefPubMed

314.

Gibson KS, Woodburn J, Porter D, Telfer S (2014) Functionally optimized orthoses for early rheumatoid arthritis foot disease: A study of mechanisms and patient experience. Arthritis Care Res (Hoboken) 66(10):1456–1464. (http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/120/CN-01022120/frame.html)CrossRef

315.

Hennessy K, Woodburn J, Steultjens MP (2012) Custom foot orthoses for rheumatoid arthritis: a systematic review. Arthritis Care Res 64:311–320CrossRef

316.

Moreira E, Jones A, Oliveira HA, Jennings F, Fernandes ARC, Natour J (2012) Effect of insoles on the rheumatoid foot. Scand J Rheumatol 45(5):363–370. (http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/417/CN-01028417/frame.html)CrossRef

317.

Rome K, Clark H, Gray J, McMeekin P, Plant M, Dixon J (2016) Clinical effectiveness and cost-effectiveness of foot orthoses for people with established rheumatoid arthritis: An exploratory clinical trial. Scand J Rheumatol. https://doi.org/10.1080/03009742.2016.1196500 CrossRefPubMed

318.

Novak P, Burger H, Tomsic M, Marincek C, Vidmar G (2009) Influence of foot orthoses on plantar pressures, foot pain and walking ability of rheumatoid arthritis patients—a randomised controlled study. Disabil Rehabil 31(8):638–645. (http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/225/CN-00704225/frame.html.)PubMedCrossRef

319.

Astin JA, Beckner W, Soeken K, Hochberg MC, Berman B (2002) Psychological interventions for rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheum 47:291–302PubMedCrossRef

320.

Dixon KE, Keefe FJ, Scipio CD, Perri LM, Abernethy AP (2007) Psychological interventions for arthritis pain management in adults: A meta-analysis. Health Psychol 26:241–250PubMedCrossRef

321.

Evers AW, Kraaimaat FW, van Riel PL, de Jong AJ (2002) Tailored cognitive-behavioral therapy in early rheumatoid arthritis for patients at risk: A randomized controlled trial. Pain 100:141–153PubMedCrossRef

322.

Savelkoul M, de Witte L, Post M (2003) Stimulating active coping in patients with rheumatic diseases: a systematic review of controlled group intervention studies. Patient Educ Couns 50:133–143PubMedCrossRef

323.

Sharpe L, Allard S, Sensky T (2008) Five-year followup of a cognitive-behavioral intervention for patients with recently-diagnosed rheumatoid arthritis: effects on health care utilization. Arthritis Rheum 59:311–316PubMedCrossRef

324.

Sharpe L, Sensky T, Timberlake N, Ryan B, Allard S (2003) Long-term efficacy of a cognitive behavioural treatment from a randomized controlled trial for patients recently diagnosed with rheumatoid arthritis. Rheumatology 42:435–441PubMedCrossRef

325.

Barsky AJ, Ahern DK, Orav EJ, Nestoriuc Y, Liang MH, Berman IT et al (2010) A randomized trial of three psychosocial treatments for the symptoms of rheumatoid arthritis. Semin Arthritis Rheum 40(3):222–232. (http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/747/CN-00781747/frame.html)PubMedPubMedCentralCrossRef

326.

Fogarty FA, Booth RJ, Gamble GD, Dalbeth N, Consedine NS (2015) The effect of mindfulness-based stress reduction on disease activity in people with rheumatoid arthritis: a randomised controlled trial. Ann Rheum Dis 74(2):472–474. (http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/246/CN-01049246/frame.html)PubMedCrossRef

327.

Hewlett S, Ambler N, Almeida C, Cliss A, Hammond A, Kitchen K et al (2011) Self-management of fatigue in rheumatoid arthritis: a randomised controlled trial of group cognitive-behavioural therapy. Ann Rheum Dis 70(6):1060–1067. (http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/651/CN-00788651/frame.html)PubMedCrossRef

328.

Knittle K, Maes S, Gucht V (2010) Psychological interventions for rheumatoid arthritis: Examining the role of self-regulation with a systematic review and meta-analysis of randomized controlled trials. Arthritis Care Res (Hoboken) 62(10):1460–1472. (http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/525/CN-00898525/frame.html)CrossRef

329.

Lumley MA, Keefe FJ, Mosley-Williams A, Rice JR, McKee D, Waters SJ et al (2014) The effects of written emotional disclosure and coping skills training in rheumatoid arthritis: A randomized clinical trial. J Consult Clin Psychol 82(4):644–658. (http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/684/CN-00998684/frame.html.)PubMedPubMedCentralCrossRef

330.

Lee MS, Shin BC, Ernst E (2008) Acupuncture for rheumatoid arthritis: a systematic review. Rheumatology 47:1747–1753PubMedCrossRef

331.

Wang C, de Pablo P, Chen X, Schmid C, McAlindon T (2008) Acupuncture for pain relief in patients with rheumatoid arthritis: A systematic review. Arthritis Rheum 59:1249–1256PubMedCrossRef

332.

Park J, Ernst E (2005) Ayurvedic medicine for rheumatoid arthritis: A systematic review. Semin Arthritis Rheum 34:705–713PubMedCrossRef

333.

Cameron M, Gagnier JJ, Chrubasik S (2011) Herbal therapy for treating rheumatoid arthritis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD002948.pub2 CrossRefPubMedPubMedCentral

334.

Macfarlane GJ, El-Metwally A, De Silva V, Ernst E, Dowds GL, Moots RJ (2011) Evidence for the efficacy of complementary and alternative medicines in the management of rheumatoid arthritis: A systematic review. Rheumatology 50:1672–1683PubMedCrossRef

335.

Wang HL, Jiang Q, Feng XH, Zhang HD, Ge L, Luo CG et al (2016) Tripterygium wilfordii hook f versus conventional synthetic disease-modifying anti-rheumatic drugs as monotherapy for rheumatoid arthritis: A systematic review and network meta-analysis. BMC Complement Altern Med 16:215PubMedPubMedCentralCrossRef

336.

Wang X, Zu Y, Huang L, Yu J, Zhao H, Wen C et al (2017) Treatment of rheumatoid arthritis with combination of methotrexate and tripterygium wilfordii: a meta-analysis. Life Sci 171:45–50PubMedCrossRef

337.

Zhang W, Shi Q, Zhao LD, Li Y, Tang FL, Zhang FC et al (2010) The safety and effectiveness of a chloroform/methanol extract of tripterygium wilfordii hook f (t2) plus methotrexate in treating rheumatoid arthritis. J Clin Rheumatol 16:375–378PubMedCrossRef

338.

Brien S, Lachance L, Prescott P, McDermott C, Lewith G (2011) Homeopathy has clinical benefits in rheumatoid arthritis patients that are attributable to the consultation process but not the homeopathic remedy: A randomized controlled clinical trial. Rheumatology (Oxford) 50(6):1070–1082. (http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/373/CN-00802373/frame.html)

339.

Kåre HB, Byfuglien Marte G, Falzon L, Olsen Sissel U, Smedslund G (2009) Dietary interventions for rheumatoid arthritis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD006400.pub2 CrossRef

340.

Jiang J, Li K, Wang F, Yang B, Fu Y, Zheng J et al (2016) Effect of marine-derived n‑3 polyunsaturated fatty acids on major eicosanoids: a systematic review and meta-analysis from 18 randomized controlled trials. PLoS ONE 11:e147351PubMedPubMedCentralCrossRef

341.

Miles EA, Calder PC (2012) Influence of marine n‑3 polyunsaturated fatty acids on immune function and a systematic review of their effects on clinical outcomes in rheumatoid arthritis (provisional abstract). Br J Nutr 107(Suppl 2):S171–184 (http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012029080/frame.html.)PubMedCrossRef

342.

Olendzki BC, Leung K, Buskirk S, Reed G, Zurier RB (2011) Treatment of rheumatoid arthritis with marine and botanical oils: Influence on serum lipids. Evid Based Complement Alternat Med 2011:827286 (http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/291/CN-00898291/frame.html)PubMedPubMedCentralCrossRef

343.

Proudman SM, Cleland LG, Metcalf RG, Sullivan TR, Spargo LD, James MJ (2015) Plasma n‑3 fatty acids and clinical outcomes in recent-onset rheumatoid arthritis. Br J Nutr 114(6):885–890. (http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/460/CN-01097460/frame.html)PubMedCrossRef

344.

Proudman SM, James MJ, Spargo LD, Metcalf RG, Sullivan TR, Rischmueller M et al (2015) Fish oil in recent onset rheumatoid arthritis: A randomised, double-blind controlled trial within algorithm-based drug use. Ann Rheum Dis 74:89–95PubMedCrossRef

345.

Prevoo ML, van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44–48PubMedCrossRef

346.

Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G et al (2003) A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology 42:244–257PubMedCrossRef

347.

Aletaha D, Smolen J (2005) The simplified disease activity index (sdai) and the clinical disease activity index (cdai): A review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 23:S100–S108PubMed

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Management der frühen rheumatoiden Arthritis

Interdisziplinäre Leitlinie

Auszug

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Blasenkarzinom – Biomarker statt Zytologie?

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin